The ovary-mediated FSH attenuation of the LH surge in the rat involves a decreased gonadotroph progesterone receptor (PR) action but not PR expression

Ana Gordon1,*, José C Garrido-Gracia1,*, Rafaela Aguilar1, Carmina Bellido1, Juan A García Velasco3, Yolanda Millan2, Manuel Tena-Sempere1, Juana Martín de las Mulas2 and José E Sánchez-Criado1

Departments of 1Cell Biology, Physiology and Immunology and 2Comparative Pathology, University of Córdoba, 14004 Córdoba, Spain
3IVI Madrid, Madrid, Spain

(Correspondence should be addressed to J E Sánchez-Criado; Email: fi1sacrj@uco.es)

*(A Gordon and J C Garrido-Gracia contributed equally to this work)

Abstract

Hyperstimulation of ovarian function with human FSH (hFSH) attenuates the preovulatory surge of LH. These experiments aimed at investigating the mechanism of ovarian-mediated FSH suppression of the progesterone (P4) receptor (PR)-dependent LH surge in the rat. Four-day cycling rats were injected with hFSH, oestradiol benzoate (EB) or vehicle during the dioestrous phase. On pro-oestrus, their pituitaries were studied for PR mRNA and protein expression. Additionally, pro-oestrous pituitaries were incubated in the presence of oestradiol-17β (E2), and primed with P4 and LH-releasing hormone (LHRH), with or without the antiprogestin RU486. After 1 h of incubation, pituitaries were either challenged or not challenged with LHRH. Measured basal and LHRH-stimulated LH secretions and LHRH self-priming were compared with those exhibited by incubated pituitaries on day 4 from ovariectomized (OVX) rats in metoestrus (day 2) injected with hFSH and/or EB on days 2 and 3. The results showed that: i) hFSH lowered the spontaneous LH surge without affecting basal LH and E2 levels, gonadotroph PR-A/PR-B mRNA ratio or immunohistochemical protein expression; ii) incubated pro-oestrous pituitaries from hFSH-treated rats did not respond to P4 or LHRH, and lacked E2-augmenting and LHRH self-priming effects and iii) OVX reversed the inhibitory effects of hFSH on LH secretion. It is concluded that under the influence of hFSH, the ovaries produce a non-steroidal factor which suppresses all PR-dependent events of the LH surge elicited by E2. The action of such a factor seemed to be due to a blockade of gonadotroph PR action rather than to an inhibition of PR expression. Journal of Endocrinology (2008) 196, 583–592

Introduction

Geiger et al. (1980) showed that treatment with follicle-stimulating hormone (FSH) at the beginning of a 4–day oestrous cycle in the rat causes a reduction of the spontaneous preovulatory luteinizing hormone (LH) release in the afternoon of pro-oestrous. The major and most relevant endocrine action of FSH on ovarian granulosa cells is the induction of specific genes (P450SCC and P450AROM) necessary for oestradiol-17β (E2) biosynthesis (reviewed in Richards 1993). Besides this steroidogenic activity, a significant number of FSH-dependent non-steroidal substances of ovarian origin with regulating activities on the synthesis and release of gonadotrophins (LH and FSH) have recently been identified. Inhibin, activin and follistatin are relatively stronger modulators of FSH secretion (Farnworth et al. 1988, de Jong 1988, Ying 1988), whereas gonadotrophin surge-inhibiting or -attenuating factor (GnSI/AF, also named attenuin; Balen 1996, Fowler & Templeton 1996, Fowler et al. 2003) and oestrogen-antagonizing factor (Schuiling et al. 1987,1999) are relatively stronger suppressors of the preovulatory LH surge.

In the rat, the preovulatory LH surge is strictly dependent on the ability of the pro-oestrous ovarian E2 surge to increase gonadotroph responsiveness to the hypothalamic decapeptide LH-releasing hormone (LHRH; Fink 1988). The spontaneous preovulatory LH surge in pro-oestrous afternoon has two components: 1) E2-augmenting LHRH-induced LH secretion and 2) LHRH self-priming (Fink 1995, Schuiling et al. 1999). The latter is the phenomenon whereby a subsequent LHRH pulse stimulates a larger LH pulse from the pituitary than the preceding LHRH pulse. The pituitary thus becomes primed by newly synthesized priming proteins (Fink 1995). Both secretory components of LH surge depend on E2-induced upregulation of progesterone (P4) receptor (PR) in the gonadotroph (Krey et al. 1973, Turgeon & Waring 1994, 2006, Chappell et al. 1999, Szabo et al. 2000, Bellido et al. 2003), the unique pituitary cell type that expresses PR. (Fox et al. 1990, Turgeon & Waring 2000, Bellido et al. 2003). The pharmacological blockade of PR with...
antiprogestins blocks both components of the LH surge in cycling rats (Sánchez-Criado et al. 1990, 2000, 2004). Thus, it is widely accepted that PR activation is an obligatory step for E2-increased pituitary response to LHRH (Chappell et al. 1999) and LHRH self-priming (Turgeon & Waring 1994). These and other (Turgeon & Waring 1990, 1991) observations explicitly demonstrate that the presence of the neuroendocrine integrator PR (Levine et al. 2001) is an absolute requirement for the transmission of E2-induced signals leading to LH surge. Accumulated evidence indicates that gonadotroph PR can be activated by the cognate ligand (Kao & Mahesh 1986) and, in a ligand-independent manner (Blaustein 2004), by LHRH intracellular signalling pathways (Turgeon & Waring 1994, Fink 1995, Garrido-Gracia et al. 2006).

The present study examined the effects of human FSH (hFSH) treatment on gonadotroph PR mRNA and protein expression and PR action (E2-augmenting LHRH-induced LH secretion and LHRH self-priming) in the cyclic rat. In addition, the involvement of the ovary in the hFSH-suppressed LH secretion was evaluated using ovariectomized (OVX) rats in metoestrus.

Materials and Methods

Animals, general conditions and surgery

Adult female Wistar rats weighing 190–210 g were housed under a 14 h light:10 h darkness cycle (light on at 0500 h) and 22 ± 2°C room temperature, with ad libitum access to rat chow and tap water. Rats were included in the experiments after showing at least three consecutive 4-day oestrous cycles (oestrus, metoestrus, dioestrus and pro-oestrus). Vaginal smears were taken 7 days/week, and the day of vaginal (oestrus, metoestrus, dioestrus and pro-oestrus). Vaginal

Drugs and treatments

Purified hFSH (Gonal-f, Serono, Aubonne, Switzerland) was dissolved at a concentration of 50 IU/ml saline. Rats were s.c. injected at 1400 h on day 2 and at 0900 h on day 3 with 10 IU of hFSH. Oestradiol benzoate (EB; Sigma Chemical Co.) was injected s.c. at the physiological doses of 10 μg/0.2 ml oil (Schuiling et al. 1987) at 0900 h on day 3. Control rats were given 0.2 ml oil/saline mixture.

Effect of hFSH and EB on serum concentrations of E2 and LH and ovulation rate

The aim of this first experiment was to determine serum concentrations of E2 and LH and the ovulation rate in cyclic rats injected with hFSH or EB. At 0900 h on pro-oestrus, eight rats per group (vehicle-, hFSH- and EB-injected rats) were lightly etherized and less than 0.4 ml blood was obtained by direct jugular venipuncture. Again, at 1900 h (the zenith, of the LH surge in our colony; Sánchez-Criado et al. 1990), another blood sample was obtained. Blood was allowed to clot, centrifuged at 4°C and the serum stored at −20°C until quantified for E2 and LH by specific RIAs. At 0900 h of the next day (day of oestrus), the oviduct was examined for the presence of eggs, which were counted under light microscopy.

Effect of hFSH and EB on PR expression

In the second experiment, PR mRNA and protein levels were determined in pituitaries from vehicle-, hFSH- and EB-injected rats. At 0900 h on pro-oestrus, rats from each of the three groups were decapitated and their anterior pituitaries collected. Pituitaries from OVX rats on day 2 (metoestrus) and killed on day 4 were used as controls. Pituitaries from each of the four groups (OVX rats and vehicle-, hFSH- or EB-injected cyclic rats), were assigned to either RT-PCR (n = 9) or immunohistochemistry analysis (n = 3).

Effect of hFSH and EB on in vitro LH pituitary responsiveness

In the third experiment, we investigated the effect of hFSH and EB treatments on LH pituitary responsiveness in intact cycling rats. Control injections consisted of 0.2 ml oil/saline mixture. At 0900 h on pro-oestrus, 20 rats per group were decapitated and the anterior pituitary glands removed and divided in halves for the incubation study.

In the fourth experiment, we evaluated in vitro the involvement of the ovary in the inhibitory effects of hFSH on LH secretion. Day 2 OVX rats were injected with hFSH on days 2 and 3 and/or with EB on day 3. Control injections consisted of 0.2 ml oil/saline mixture. At 0900 h on day 4, rats were decapitated and the anterior pituitary glands were removed and divided in halves for the incubation study. All pituitaries except those from OVX rats injected with vehicle were incubated with E2.

Hemipituitary incubation protocol

Incubation of pituitaries was carried out as described previously (Bellido et al. 2003). Briefly, halves of anterior pituitaries were incubated at 37°C with constant shaking (60 cycles/min) in an atmosphere of 95% O2 and 5% CO2. Each vial contained 1 ml Dulbecco’s modified Eagle’s medium, without 1-glutamine and phenol red, containing glucose (4.5 g/l), 10−8 M E2 (Sigma) and BSA (0.1% w/v), pH 7.4. After 1 h of pre-incubation, hemipituitaries were incubated for 75 min. During the 1-h pre-incubation period, no test substances were added except for RU486 (Fig. 1). During the first 60 min of the incubation period, fresh medium containing priming agents was added (Fig. 1). Test substances included: medium alone, 10−8 M LHRH (Peninsula 7201, Peninsula Lab. Inc., Merseyside, UK),
100 nM P4 (Sigma) and LHRH + 10 nM antiprogestin RU486 (Exelgyn, Paris, France). The first LHRH challenge lasted 15 min (Fig. 1); after, fresh medium without LHRH was added. Finally, during the last 15 min of the incubation period fresh medium containing LHRH was added. Afterwards, medium was removed for the determination of LH concentration and pituitary responsiveness (Fig. 1). Doses of hormones and drugs used and timing of treatments derive from previous papers (Denner et al. 1990, Turgeon & Waring 1991, Sánchez-Criado et al. 2004, 2006).

**RIA of LH and E2**

Concentrations of LH in serum and incubation media were measured in duplicate by RIA using a double antibody method with kits supplied by the NIH (Bethesda, MD, USA) and a previously described microassay method (Sanchez-Criado et al. 1990). Rat LH-I-10 was labelled with 125I by the chloramine T method. All serum and media samples were assayed in the same assay. Intra-assay coefficient of variation was 8%, and assay sensitivity was 3.75 pg/tube. LH concentrations were expressed as ng/ml serum of the reference preparation LH-rat-RP-3. Serum E2 concentrations were determined in duplicate using a commercially obtained kit (Diagnosis Products Corporation, Los Angeles, CA, USA). The sensitivity of the assay was 1 pg/tube, and the intra-assay coefficient of variation was 7%. E2 concentrations were expressed as pmol/l serum.

**PR-AB and PR-B mRNA analysis by semi-quantitative RT-PCR in rat anterior pituitary**

Anterior pituitaries were immediately frozen in liquid nitrogen and stored at -80 °C until used for RNA analysis. RT-PCR, optimized for semiquantitative detection, was used to analyse relative expression levels of PR-AB and PR-B mRNA in pituitaries from experimental groups. For comparative purposes, pituitary PR-AB and PR-B mRNA expression on day 4 in O VX rats on day 2 (metoestrus) was also monitored. Total RNA was isolated from pituitary samples using the single-step, acid guanidinium thiocyanate–phenol–chloroform extraction method (Chomczynski & Sacchi 1987). Analysis of total PR-AB mRNA expression was carried out using a primer pair flanking a 326 bp coding area common to both PR-A and PR-B isoforms (Szabo et al. 2000, Bellido et al. 2003), while assessment of PR-B mRNA levels was performed using a primer combination that enables amplification of a 221 bp fragment from the PR unique to the functional B isoform (Tena-Sempere et al. 2004). In addition, to provide an appropriate internal control, parallel amplification of a 249 bp of the S11 ribosomal protein mRNA was carried out for each sample. For amplification of the targets, RT-PCR was run in two separate steps. In addition, to enable appropriate amplification of specific signals and S11 ribosomal protein, transcripts were carried out in separate reactions with different number of cycles but using similar amounts of the corresponding cDNA templates, generated in single RT reactions, as previously described (Tena-Sempere et al. 2004). PCRs consisted of a first denaturing cycle at 97 °C for 5 min, followed by a variable number of amplification cycles defined by denaturation at 96 °C for 30 s, annealing for 30 s and extension at 72 °C for 1 min. A final extension cycle of 72 °C for 15 min was included. Annealing temperatures were adjusted for each target: 55 °C for PR-AB, 56 °C for PR-B and 58 °C for RP-S11. These cycling conditions had previously been optimized to ensure amplification of each transcript in the exponential phase PCR (Bellido et al. 2003, Tena-Sempere et al. 2004). Semiquantitative data from RNA assays were expressed as mean ± S.E.M.
from at least three independent determinations within each experimental group. In all assays, liquid controls and reactions without RT were included, yielding negative amplification (data not shown).

**Immunoreactivity of PR protein in the rat gonadotroph**

The immunohistochemical study was performed on dewaxed and rehydrated 3 μm thick tissue sections of formalin-fixed, paraffin-embedded tissue samples. The commercial mouse monoclonal anti-human PR antibody clone PR10A9, raised against the recombinant hormone-binding domain of human PR located on the C-terminal domain (Kastner et al. 1990) of PR (Immunotech, Marseille, France), diluted 1:15 000, and the avidin–biotin–peroxidase complex technique (Vector, Burlingame, CA, USA) were used as previously described (Sánchez-Criado et al. 2004). Accordingly, the antibody recognized both A and B isoforms of PR. Tissue sections from similarly processed samples of rat uterus and human breast carcinoma were used as positive controls. The specificity of similarly processed samples of rat uterus and human breast recognized both A and B isoforms of PR. Tissue sections from completely at 10°C the cognate ligand for 1 h at 37°C was counted in 15 high power fields (all cases. The number of cells immunoreactive to PR antibody counterstaining was performed with Mayer’s haematoxylin in the cases under study was used as negative control. Nuclear dilution as the specific primary antibody in tissue sections of physiological title of the hormone. Substitution of the specific

**Statistical analysis**

Statistical analysis was performed by ANOVA to test for significant differences among groups. When significant differences existed, ANOVA was followed by the Student–Newman–Keuls multiple range test to compare means. Significance was considered at the 0.05 level.

**Results**

**Effects of hFSH and EB on vaginal cytology and uterine ballooning**

On pro-oestrus in intact cycling rats injected with vehicle, hFSH or EB, and on day 4 in day 2 OVX rats injected with EB, with or without hFSH, vaginal smears displayed, predominantly, nucleated epithelial cells characteristic of vaginal pro-oestrus. The uterus was ballooned in all rats except for OVX rats injected with vehicle. Uterine ballooning was more evident in EB- than in vehicle- or hFSH-injected rats.

**Effects of hFSH and EB on serum concentrations of E2 and LH during pro-oestrus and on the number of ova/ovulating rat on oestrus**

In the morning of pro-oestrus, no differences in serum LH concentrations (0.6±0.1 ng/ml) were found among groups of intact cycling rats, whereas serum E2 concentrations were significantly increased in both hFSH- and EB-treated rats (Fig. 2A). In the afternoon of pro-oestrus, coinciding with the peak of the LH surge, serum LH concentrations increased in EB treated, but decreased in hFSH-treated intact cycling rats (Fig. 2B). No differences were noted in the number of ova shed in the oviducts between vehicle- and EB-treated rats. However, the number of ova shed in the morning of oestrus was increased in hFSH-treated rats (Fig. 2C).

**Effects of hFSH and EB on pituitary PR-AB and PR-B mRNA and gonadotroph PR protein expression in pro-oestrus**

Compared with the levels measured in pituitaries from OVX rats, both PR-AB and PR-B mRNA levels were significantly increased in pituitaries from cyclic rats injected with vehicle, hFSH and EB (Fig. 3). Moreover, the levels of both PR-AB and PR-B mRNA were significantly reduced, by 37.4 and 34.8%, respectively, in pituitaries from hFSH-injected cyclic rats with respect to the mRNA levels seen in pituitaries from vehicle-injected pro-oestrous rats (Fig. 3). This similar percentage reduction of PR-AB and PR-B mRNA directly implies that the PR-A/PR-B transcripts ratio did not change after hFSH treatment. No differences were found between vehicle- and hFSH-injected rats either in the intensity of staining or the number of cells immunoreactive to PR antibody in the nuclei of anterior pituitary cells (Fig. 4). It is worth noting the close correlation (r=0.955) observed between E2 levels (Fig. 2A) and the number of pituitary PR-positive cells (Fig. 4) in rats injected with vehicle or treated with hFSH or EB.

**Pro-oestrous pituitary responsiveness to LHRH in cycling rats treated with hFSH or EB and primed in vitro with LHRH, P4 and LHRH+RU486: effect of OVX on metoestrus**

Pituitaries from pro-oestrous cycling rats injected with vehicle exhibited: increased LH secretion in response to LHRH; LHRH self-priming that was significantly reduced by addition of RU486 to the media and P4 potentiation of LHRH-stimulated LH secretion (Fig. 5). All these responses were significantly (P<0.05) augmented in pituitaries from pro-oestrous cycling rats injected with EB. In sharp contrast, pituitaries from hFSH-injected rats did not respond to LHRH, and did not exhibit LHRH self-priming or P4-potentiated LHRH-stimulated LH secretion. No differences in basal LH secretion among pituitaries from vehicle-, hFSH- or EB-treated rats were noted (Fig. 5).

In comparison with pituitary responsiveness from day 2 OVX rats injected with vehicle (Fig. 6A), pituitaries from EB-treated OVX rats showed on day 4 LHRH-stimulated LH secretion,
LHRH self-priming, P4 potentiation of LHRH-stimulated LH secretion and RU486 blockade of LHRH self-priming. These effects of EB in OVX rats, which did not differ from those of intact rats in pro-oestrus (Fig. 5), were not affected by hFSH treatment (Fig. 6).

**Discussion**

The present results first show that ovarian stimulation with hFSH during the dioestrous phase in the cyclic rat decreased

---

**Figure 2** Serum levels of oestradiol-17β and LH at (A) 0900 and (B) 1900 h on pro-oestrus respectively, and ovulation rate at (C) 0900 h of the next day (oestrus) in intact cycling rats injected with vehicle, hFSH or EB (see legend of Fig. 1 for details of treatment). Values are given as mean ± S.E.M. of eight rats per group. *P < 0.05 versus vehicle-injected rats. ANOVA and Student–Newman–Keuls multiple range test. The morning concentrations of LH (0.6 ± 0.1 ng/ml) are not shown.

**Figure 3** Expression of total progesterone receptor (PR)-AB and PR-B mRNA in pituitaries from intact cycling rats on pro-oestrus injected with vehicle, hFSH or EB (see legend of Fig. 1 for details of treatment). For comparative purposes, pituitary PR mRNA levels at 0900 h on day 4 in rats ovariectomized (OVX) at 0900 h on day 2 (metoestrus) are also shown. Upper panel: representative ethidium bromide-stained gel electrophoresis of PR-AB, PR-B and RP-S11 cDNA fragments amplified by semi-quantitative RT-PCR from total pituitary RNA in the experimental groups. Lower panel: semi-quantitative data on the steady-state levels of total PR-AB and PR-B mRNA in experimental groups. Relative expression levels were obtained, in each sample, by normalization of absolute optical densities (ODs) of the specific target to that of RP-S11 signal. Expression levels of PR-AB and PR-B transcripts in OVX rats were taken as 100%, and the other values were normalized accordingly. Values are given as mean ± S.E.M. of nine independent determinations. *P < 0.05 versus OVX and b P < 0.05 versus vehicle. ANOVA and Student–Newman–Keuls multiple range test.

LHRH self-priming, P4 potentiation of LHRH-stimulated LH secretion and RU486 blockade of LHRH self-priming. These effects of EB in OVX rats, which did not differ from those of intact rats in pro-oestrus (Fig. 5), were not affected by hFSH treatment (Fig. 6).
serum LH concentration in pro-oestrous afternoon, a basic finding wholly in agreement with previously reported data (Geiger et al. 1980, de Koning et al. 1987, Culler 1992, Schuiling et al. 1999); secondly, that hFSH stimulated the production
of some ovarian factor(s) other than E2 that reduced the preovulatory LH surge, but not basal LH secretion; and thirdly, that the ovary-mediated hFSH inhibition of LH surge was exerted on gonadotroph PR action.

Increases in both serum E2 levels in the morning of pro-oestrus and ovulation rate the following day were observed in hFSH-treated cycling rats. This hFSH-stimulated ovarian activity was associated, however, with a decrease in LH secretion in the afternoon of pro-oestrus. Geiger et al. (1980) proposed the existence of an inappropriate feedback of the increased E2 levels on the LH surge as the mechanism underlying the inhibitory effect of FSH. Nevertheless, administration of EB on dioestrus to intact cyclic rats, a treatment that increases E2 serum concentrations in the morning of pro-oestrus without ovarian stimulatory activity, did not reduce serum LH concentrations in pro-oestrous afternoon. By contrast, physiological doses (Schuiling et al. 1987) of injected EB acted in a very convincing positive feedback manner (Fink 1988) resulting in an increased magnitude of the LH surge. Also, the observed inhibitory effect of hFSH on in vitro LH secretion from incubated pituitaries was absent in pituitaries from OVX rats. All these facts demonstrate conclusively that hFSH stimulates the production of some factor(s) of ovarian origin other than E2, and that these hFSH-dependent ovarian factor(s) inhibit the preovulatory LH surge. A drop in circulating levels of such FSH-dependent ovarian peptides with LH surge-inhibitory bioactivity has been adduced as playing a critical role in switching from negative to positive the action of E2 on LH secretion (Balen & Jacobs 1991, Fowler & Templeton 1996, Fowler et al. 2003).

The positive feedback effect of E2 at the pituitary level includes: 1) induction of PR expression in gonadotrophs (Fox et al. 1990, Sánchez-Criado et al. 2004, present results), 2) increase of gonadotroph responsiveness to LHRH (Aiyer & Fink 1974, present results) and 3) induction of gonadotrophin-releasing hormone self-priming (Turgeon & Waring 1994, present results). These E2 effects trigger, in the obligatory presence of PR (Chappell et al. 1999), the preovulatory LH surge (Fink 1988). E2-dependent PR can be activated by the cognate ligand P4 from ovarian granulosa cells during pro-oestrous afternoon and evening (Rao & Mahesh 1986) or, in a ligand-independent manner (Blaustein 2004), by intracellular signals of LHRH:cAMP and/or protein kinase C (PKC) (Turgeon & Waring 1994, Fink 1995, Garrido-Gracia et al. 2006) shortly after the noon in pro-oestrus (Fink 1988). All these facts, and the present in vitro observations of the inhibitory effect of RU486 on LHRH self-priming, demonstrated that the presence of PR and its activation are absolute requirements for the transmission of E2-induced signals leading to the LH surge. Treatment with FSH reduced only the magnitude of the LH surge with no effect on basal LH secretion (Geiger et al. 1980, present experiments), and it would appear that FSH may well decrease the preovulatory LH release by affecting PR expression and/or action (Garrido-Gracia et al. 2007).

Unexpectedly, an inhibitory effect of hFSH on pituitary PR–A and PR–B transcripts was unmistakably proved in these
experiments. There is currently no satisfactory explanation for this effect of hFSH, which merits further independent investigation. However, the results clearly indicate that the inhibitory influence of this hFSH-dependent ovarian factor on LH secretion takes place at the gonadotroph PR post-translational level rather than at E2-dependent (Kastner et al. 1990) PR mRNA transcription or PR protein translation levels. This is because no effects of hFSH on PR-A/PR-B mRNA ratio or total immunoreactive PR protein were noted. In addition, hFSH treatment did not affect, either in vivo or in vitro, basal LH secretion, a finding also in agreement with the PR-independent character of the negative E2 feedback on LH secretion (Chappell et al. 1999, Garrido-Gracia et al. 2007). In full agreement with others (Manni et al. 1981), a positive translational effect of the E2 background on PR protein was evidenced. This, as well as the effects of hFSH on PR transcripts, could easily be due to the differential time-course expression and/or stability of PR mRNA and protein (Lee Kraus & Katzenellenbogen 1993).

Although the FSH-dependent ovarian hormones inhibitin (Culler 1992, Byrne et al. 1995) and follistatin (Wang et al. 1990) have been postulated to have GnSI/A bioactivity, the majority of evidence support the view that the inhibitory effect of exogenous FSH on the LH surge is mainly due to the activity of the putative GnSI/AF (de Koning et al. 1987, Balen & Jacobs 1991, Balen 1996, Byrne et al. 1996, Fowler & Templeton 1996, de Koning et al. 2001, Fowler et al. 2003). GnSI/AF is a non-steroidal, non-inhibin ovarian hormone of ~60–70 kDa (Fowler et al. 2003) secreted by granulosa cells in response to FSH with the specific bioactivity of inhibiting LHRH self-priming (Balen 1996, Fowler & Templeton 1996, Fowler et al. 2003). This action of GnSI/AF keeps LH concentrations low despite the positive feedback effect of E2 at the pituitary level during the late follicular phase (de Koning 1995). In addition, an FSH-dependent ovarian non-steroidal oestrogen-antagonizing factor, different from GnSI/AF, has been postulated to specifically suppress the sensitizing effect of E2 on LHRH-stimulated LH secretion (Schuiling et al. 1999). The results of the present experiments demonstrate that hFSH treatment, like RU486 (Rao & Mahesh 1986, Sánchez-Criado et al. 1990), reduced both PR-dependent E2 actions and, accordingly, attenuated the PR-dependent (Chappell et al. 1999) LH surge.

Irrespective of the nature of the ovarian factor involved in the FSH suppression of preovulatory LH secretion, it acts on gonadotroph membrane receptors different from those of LHRH (Fowler & Templeton 1996). This implies the existence of an intracellular functional antagonism between GnSI/AF and LHRH (de Koning 1995). Though we cannot rule out an effect through other pathways, present results have shown that the action of the putative ovarian GnSI/AF must have suppressive effects on gonadotroph PR activation through interference with the actions of P4 and the second messenger pathway of LHRH in the gonadotroph. In perfused rat hemipituitaries, steroid-free bovine follicular fluid, which possesses GnSI/AF bioactivity, antagonizes the priming action of 8-bromo-cAMP and phorbol 12-myristate 13-acetate (PMA) on LH secretion (Tijssen et al. 1997). Also, it appears that GnSI/AF from follicular fluid of women undergoing superovulation treatments suppresses the potentiating effect of E2, P4 and PMA on LHRH-stimulated LH secretion (Fowler & Templeton 1996). These findings indicate that GnSI/AF has widespread suppressive effects on the second messenger pathway transducing the LHRH signal within the gonadotroph. In the present experiments, neither P4 nor LHRH potentiated LHRH effect on LH secretion in FSH-treated cycling rats, even in the presence of both E2 and E2-dependent PR. This ovary-mediated effect of hFSH could be pointing to an inefficient response of gonadotroph PR to physiological phosphorylation/activation induced by P4 and PKA or PKC (Denner et al. 1990, Zhang et al. 1994), which are ligand-dependent and -independent activators of PR, respectively. It has been found that E2 inhibits PR action and LHRH self-priming by activating membrane ERz of the gonadotroph both in vivo (Sánchez-Criado et al. 2005) and in vivo (Garrido-Gracia et al. 2007). The inhibitory action of activated membrane ERz on LH secretion is reverted by inhibition of intracellular phosphatases and mimicked by the stimulation of protein phosphatases (Sánchez-Criado et al. 2006). Similarly, intracellular signals of the obligatory activation of gonadotroph membrane receptors with GnSI/AF may have blocked both P4-dependent and ligand-independent phosphorylation/activation of E2-induced expression of PR in gonadotrophs. Whether or not the inhibitory action of FSH on LH surge is the result of an imbalance of phosphorylase/phosphatase activities on the phosphoprotein transcription factor PR (Evans 1988, Mangelsdorf et al. 1995) in the gonadotroph is currently under investigation.

Acknowledgements

This study was subsidized by grants (BFU2005-01443 and AGL2006-09016/GAN) from DGICYT and P07-CVI-2559 from CICE-Junta de Andalucia (Spain). The authors are grateful to the National Hormone and Pituitary Program (Baltimore, MD, USA) for the LH RIA kit and to Teresa Recio for technical assistance. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Fowler PA & Templeton A 1996 The nature and function of putative gonadotropin surge – attenuating/inhibiting factor (GnSI/AF). *Endocrine Reviews* **17** 103–120.


Fowler PA & Templeton A 1996 The nature and function of putative gonadotropin surge – attenuating/inhibiting factor (GnSI/AF). *Endocrine Reviews* **17** 103–120.


Received in final form 6 November 2007

Accepted 4 December 2007

Made available online as an Accepted Preprint

4 December 2007